Agenus | AGEN - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
AbbVie USD 5.57B 2.9B 2026-03
Agenus USD -10.61M 263.52M 2025-12
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Celldex Therapeutics USD -81.32M 14.27M 2025-12
CSL USD 2.61B 1.21B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 343.6M 46.34M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
J&J USD 7.82B 2.86B 2026-03
Jiangsu Hengrui CNY 2.56B 261.24M 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -36.77M 21.84M 2026-03
Merck EUR 401M 886.1M 2025-12
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Veracyte USD 29.97M 10.66M 2026-03